The KI Psychiatric Genomics Institute (KI-PGI) is a systematic program established to evaluate the epidemiological, molecular, and cellular effects of genetic risk loci for psychiatric disorders, such as schizophrenia and depression.
KI-PGI is located at the Department of Medical Epidemiology and Biostatistics (MEB) at Karolinska Institutet. The director of KI-PGI is Professor Patrick Sullivan and co-director is Principal Researcher Lu Yi.
Psychiatric genomics has achieved unprecedented advances. After a century of uncertain progress and debate about the nature of severe psychiatric disorders, we now possess extraordinary new knowledge about the fundamental genetic architectures. A decade ago, there was perhaps one solid finding for schizophrenia, and there are now over XX loci that meet consensus criteria for significance and replication.
The major funder for the KI-Psychiatric Genomics Institute (KI-PGI) is the Swedish research council (Vetenskapsrådet) (grant no 583-2013-8865). Additional funding comes from the EU (the COSYN project, H2020 grant no. 667301; the CoMorMent project H2020 grant no. 847776; and the REALMENT project H2020 grant no. 964874), and NIMH (The Swedish schizophrenia study - S3, grant no. R01 MH077139-07 RPPR; the Trans-Nordic Study of Extreme Major Depression, grant no. R01 MH123724).